Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference

Rhea-AI Summary

Immuneering (Nasdaq: IMRX) announced management will present at the Piper Sandler 37th Annual Healthcare Conference in New York City.

Presenters include Ben Zeskind (CEO), Igor Matushansky M.D. (CMO), Harold “E.B.” Brakewood (CBO) and Mallory Morales, CPA (CAO, Treasurer). Format: company presentation and 1x1 investor meetings. Presentation time: December 4, 11:10–11:30 a.m. ET, Staten Island Track (Kennedy 1, 4th Floor). The presentation will be webcast live and archived in the Investor Relations section under Events & Presentations.

NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Piper Sandler 37^th Annual Healthcare Conference in New York City. Participating will be Ben Zeskind, Co-founder and Chief Executive Officer, Igor Matushansky M.D., Chief Medical Officer, Harold “E.B.” Brakewood, Chief Business Officer and Mallory Morales, CPA, Chief Accounting Officer, Treasurer.

Format: Company Presentation and 1x1 investor meetings.

Presentation time: December 4, 11:10-11:30 a.m. ET, Staten Island Track (Kennedy 1, 4th Floor).

The presentation will be webcast live and archived in the Investor Relations section of Immuneering’s website at Events & Presentations | Immuneering Corporation.

About Immuneering Corporation

Immuneering is a clinical-stage oncology company focused on keeping cancer patients alive and helping them thrive. The Company is developing an entirely new category of cancer medicines, Deep Cyclic Inhibitors. Immuneering’s lead product candidate, atebimetinib, is an oral, once-daily Deep Cyclic Inhibitor of MEK, designed to improve durability and tolerability across many cancer indications, including MAPK pathway-driven tumors such as pancreatic cancer. Atebimetinib is currently in a Phase 2a trial in patients with advanced solid tumors including pancreatic cancer. The Company’s development pipeline also includes early-stage programs. For more information, please visit www.immuneering.com.

Media Contact:
Carson Creehan
202-878-8330
Carson.creehan@padillaco.com

Investor Contact:
Laurence Watts
619-916-7620
laurence@newstreetir.com

FAQ

When will Immuneering (IMRX) present at the Piper Sandler 37th Annual Healthcare Conference?

Immuneering will present on December 4, 2025 from 11:10–11:30 a.m. ET.

Who from Immuneering (IMRX) will speak at the Piper Sandler conference?

Speakers are Ben Zeskind (CEO), Igor Matushansky M.D. (CMO), Harold E.B. Brakewood (CBO) and Mallory Morales, CPA (CAO, Treasurer).

How can investors watch Immuneering's (IMRX) presentation live on December 4?

The presentation will be webcast live and an archive will be available in the company's Investor Relations Events & Presentations section.

What is the format of Immuneering's (IMRX) appearance at the Piper Sandler conference?

Format includes a company presentation and one-on-one investor meetings.

Where is Immuneering's (IMRX) presentation location at the conference?

The presentation is scheduled for the Staten Island Track (Kennedy 1, 4th Floor) in New York City.

Will Immuneering (IMRX) make the conference presentation recording available after the event?

Yes, the presentation will be archived in the Investor Relations Events & Presentations section on the company's website.